e-learning
resources
Copenhagen 2005
Tuesday 20.09.2005
Exploring alternative mechanisms and treatments
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The usage of thiotriazolin in complex treatment of patients with community acquired pneumonia
I. A. Ilyuk (Vinnitsa, Ukraine)
Source:
Annual Congress 2005 - Exploring alternative mechanisms and treatments
Session:
Exploring alternative mechanisms and treatments
Session type:
Thematic Poster Session
Number:
3709
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. A. Ilyuk (Vinnitsa, Ukraine). The usage of thiotriazolin in complex treatment of patients with community acquired pneumonia. Eur Respir J 2005; 26: Suppl. 49, 3709
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Evaluation of clinical efficiency of thiotriazolin in complex treatment of patients with community acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 669s
Year: 2006
The clinical efficiency of thiotriazolin in complex treatment of patients with community acquired pneumonia of the 3
rd
group
Source: Eur Respir J 2007; 30: Suppl. 51, 548s
Year: 2007
The usage of laferon in treatment of patients with community acquired pneumonia (CAP)
Source: Eur Respir J 2007; 30: Suppl. 51, 675s
Year: 2007
Using roncoleukine in basic therapy of patients with community acquired pneumonia
Source: Eur Respir J 2002; 20: Suppl. 38, 443s
Year: 2002
Improving outcome in elderly patients with pneumonia
Source: Annual Congress 2005 - Antibiotic therapy: short- and long-term outcomes in LRTI
Year: 2005
The general evaluation of community acquired pneumonia patients treated in our clinic
Source: Eur Respir J 2004; 24: Suppl. 48, 414s
Year: 2004
Therapeutic regimens in community acquired pneumonia (CAP): association with patients characteristics and outcomes
Source: Annual Congress 2008 - Lower respiratory tract infection: from outbreak to prognostic tests
Year: 2008
The general evaluation of elderly patients with community acquired pneumonia
Source: Eur Respir J 2004; 24: Suppl. 48, 412s
Year: 2004
Clinical presentation and evolution of community acquired pneumonia in older patients
Source: Annual Congress 2012 - Management of pneumonia due to hospital pathogens
Year: 2012
Effectiveness of empirical treatment of community acquired pneumonia requiring hospitalization
Source: Eur Respir J 2006; 28: Suppl. 50, 166s
Year: 2006
Health care associated pneumonia versus community acquired pneumonia: Comparison of etiology, treatment and prognosis
Source: Annual Congress 2012 - Viral infections and rare respiratory infections
Year: 2012
Quality-indicators and prognostics in CAP in three populations
Source: Annual Congress 2005 - Community-acquired pneumonia: clinical approaches
Year: 2005
A prospective comparison of nursing home acquired pneumonia with community acquired pneumonia
Source: Eur Respir J 2001; 18: 362-368
Year: 2001
Influence of medical comorbidities in patients with community acquired pneumonia
Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools
Year: 2010
Validation of a computer predictive model to stratify risk and site of care in community acquired pneumonia (CAP)
Source: Annual Congress 2005 - Community-acquired pneumonia: clinical approaches
Year: 2005
Progress of quality indicator rates regarding treatment of patients hospitalized in Germany due to community acquired pneumonia (CAP)
Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools
Year: 2010
Cytokine-based prediction of aetiology in community acquired pneumonia
Source: International Congress 2017 – CAP: severity scores, risk groups and biomarkers
Year: 2017
The prognostic importance of plasma D-dimer levels in patients with community acquired pneumonia
Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia
Year: 2007
Healthcare-associated pneumonia among hospitalized patients. Is it really different from community acquired pneumonia?
Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections
Year: 2012
Influence on the prognosis of misuse of antibiotics prior to admission in patients with community acquired pneumonia
Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept